These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30339969)

  • 1. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    Tian T; Shan L; Yang W; Zhou X; Shui R
    Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
    BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    Lips EH; Mulder L; Oonk A; van der Kolk LE; Hogervorst FB; Imholz AL; Wesseling J; Rodenhuis S; Nederlof PM
    Br J Cancer; 2013 May; 108(10):2172-7. PubMed ID: 23558900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    Vos S; Moelans CB; van Diest PJ
    Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
    Lips EH; Laddach N; Savola SP; Vollebergh MA; Oonk AM; Imholz AL; Wessels LF; Wesseling J; Nederlof PM; Rodenhuis S
    Breast Cancer Res; 2011 Oct; 13(5):R107. PubMed ID: 22032731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
    J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
    Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Tanino H; Kosaka Y; Nishimiya H; Tanaka Y; Minatani N; Kikuchi M; Shida A; Waraya M; Katoh H; Enomoto T; Sengoku N; Kajita S; Hoffman RM; Watanabe M
    PLoS One; 2016; 11(12):e0165721. PubMed ID: 27935989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM
    Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Lips EH; Benard-Slagter A; Opdam M; Scheerman CE; Wesseling J; Hogervorst FBL; Linn SC; Savola S; Nederlof PM
    Breast Cancer Res; 2020 Jul; 22(1):79. PubMed ID: 32711554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
    BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B
    J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Khan F; Agarwal P; Gupta S; Maurya MK; Singh P; Agarwal A; Singh K; Sonkar AA; Goel MM
    Indian J Med Res; 2023 Jan; 158(1):47-54. PubMed ID: 37602586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.